These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36506255)

  • 1. Differentiating Oncocytic Renal Tumors from Chromophobe Renal Cell Carcinoma: Comparison of Peak Early-phase Enhancement Ratio to Clinical Risk Factors and Rater Predictions.
    Patel HD; Huai K; Elliott N; Thorson DL; Rac G; Picken MM; Quek ML; Bova D; Gupta GN
    Eur Urol Open Sci; 2022 Dec; 46():8-14. PubMed ID: 36506255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma.
    Amin J; Xu B; Badkhshan S; Creighton TT; Abbotoy D; Murekeyisoni C; Attwood KM; Schwaab T; Hendler C; Petroziello M; Roche CL; Kauffman EC
    Clin Cancer Res; 2018 Aug; 24(16):3898-3907. PubMed ID: 29752278
    [No Abstract]   [Full Text] [Related]  

  • 3. Aorta-Lesion-Attenuation-Difference (ALAD) on contrast-enhanced CT: a potential imaging biomarker for differentiating malignant from benign oncocytic neoplasms.
    Dhyani M; Grajo JR; Rodriguez D; Chen Z; Feldman A; Tambouret R; Gervais DA; Arellano RS; Hahn PF; Samir AE
    Abdom Radiol (NY); 2017 Jun; 42(6):1734-1743. PubMed ID: 28197683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic utility of vimentin, CD117, cytokeratin-7 and caveolin-1 in differentiation between clear cell renal cell carcinoma, chromophobe renal cell carcinoma and oncocytoma.
    El-Shorbagy SH; Alshenawy HA
    J Microsc Ultrastruct; 2017; 5(2):90-96. PubMed ID: 30023241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of the Aortic-Lesion-Attenuation-Difference (ALAD) and Peak Early-Phase Enhancement Ratio (PEER) to differentiate benign from malignant renal masses.
    Kahn AE; Lomax SJ; Bajalia EM; Ball CT; Thiel DD
    Can J Urol; 2020 Aug; 27(4):10278-10284. PubMed ID: 32861252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of specific contrast-enhanced CT regions of interest to differentiate renal oncocytomas from small clear cell and chromophobe renal cell carcinomas.
    Qu JY; Jiang H; Wang XF; Song XH; Hao CJ
    Diagn Interv Radiol; 2022 Nov; 28(6):555-562. PubMed ID: 36550755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of computed tomography findings between renal oncocytomas and chromophobe renal cell carcinomas.
    Choi JH; Kim JW; Lee JY; Han WK; Rha KH; Choi YD; Hong SJ; Yoon YE
    Korean J Urol; 2015 Oct; 56(10):695-702. PubMed ID: 26495070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Aorta-Lesion-Attenuation Difference on Preoperative Contrast-enhanced Computed Tomography Scan to Differentiate Between Malignant and Benign Renal Tumors.
    Grajo JR; Terry RS; Ruoss J; Noennig BJ; Pavlinec JG; Bozorgmehri S; Crispen PL; Su LM
    Urology; 2019 Mar; 125():123-130. PubMed ID: 30552939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DOG1, cyclin D1, CK7, CD117 and vimentin are useful immunohistochemical markers in distinguishing chromophobe renal cell carcinoma from clear cell renal cell carcinoma and renal oncocytoma.
    Zhao W; Tian B; Wu C; Peng Y; Wang H; Gu WL; Gao FH
    Pathol Res Pract; 2015 Apr; 211(4):303-7. PubMed ID: 25596994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Automated differentiation of benign renal oncocytoma and chromophobe renal cell carcinoma on computed tomography using deep learning.
    Baghdadi A; Aldhaam NA; Elsayed AS; Hussein AA; Cavuoto LA; Kauffman E; Guru KA
    BJU Int; 2020 Apr; 125(4):553-560. PubMed ID: 31901213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a DNA Methylation-Based Diagnostic Signature to Distinguish Benign Oncocytoma From Renal Cell Carcinoma.
    Brennan K; Metzner TJ; Kao CS; Massie CE; Stewart GD; Haile RW; Brooks JD; Hitchins MP; Leppert JT; Gevaert O
    JCO Precis Oncol; 2020; 4():. PubMed ID: 33015531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sporadic oncocytic tumors with features intermediate between oncocytoma and chromophobe renal cell carcinoma: comprehensive clinicopathological and genomic profiling.
    Liu YJ; Ussakli C; Antic T; Liu Y; Wu Y; True L; Tretiakova MS
    Hum Pathol; 2020 Oct; 104():18-29. PubMed ID: 32673684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of aorta-lesion-attenuation difference on preoperative contrast-enhanced computed tomography scan to differentiate between malignant and benign oncocytic renal tumors.
    Grajo JR; Batra NV; Bozorgmehri S; Magnelli LL; Pavlinec J; O'Malley P; Su LM; Crispen PL
    Abdom Radiol (NY); 2021 Jul; 46(7):3269-3279. PubMed ID: 33665734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amylase α-1A (AMY1A): a novel immunohistochemical marker to differentiate chromophobe renal cell carcinoma from benign oncocytoma.
    Jain S; Roy S; Amin M; Acquafondata M; Yin M; Laframboise W; Bastacky S; Pantanowitz L; Dhir R; Parwani A
    Am J Surg Pathol; 2013 Dec; 37(12):1824-30. PubMed ID: 24225843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring Multiphoton Microscopy as a Novel Tool to Differentiate Chromophobe Renal Cell Carcinoma From Oncocytoma in Fixed Tissue Sections.
    Jain M; Robinson BD; Wu B; Khani F; Mukherjee S
    Arch Pathol Lab Med; 2018 Mar; 142(3):383-390. PubMed ID: 29219617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative computer-aided diagnostic algorithm for automated detection of peak lesion attenuation in differentiating clear cell from papillary and chromophobe renal cell carcinoma, oncocytoma, and fat-poor angiomyolipoma on multiphasic multidetector computed tomography.
    Coy H; Young JR; Douek ML; Brown MS; Sayre J; Raman SS
    Abdom Radiol (NY); 2017 Jul; 42(7):1919-1928. PubMed ID: 28280876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness Analysis of
    Su ZT; Patel HD; Huang MM; Meyer AR; Pavlovich CP; Pierorazio PM; Javadi MS; Allaf ME; Rowe SP; Gorin MA
    Eur Urol Focus; 2021 Jul; 7(4):827-834. PubMed ID: 32115400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of Chromophobe Renal Cell Carcinoma with
    Rowe SP; Murtazaliev S; Oldan JD; Kaufmann B; Khan A; Allaf ME; Singla N; Pavlovich CP; De Marzo AM; Baraban E; Gorin MA; Solnes LB
    Mol Imaging Biol; 2024 Oct; 26(5):768-773. PubMed ID: 39078524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oncocytoma versus chromophobe renal cell carcinoma: Is there something in between?].
    Lüders C; Kristiansen G
    Pathologe; 2016 Mar; 37(2):153-8. PubMed ID: 26925847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-generation RNA Sequencing-based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms.
    Skala SL; Wang X; Zhang Y; Mannan R; Wang L; Narayanan SP; Vats P; Su F; Chen J; Cao X; Siddiqui J; Argani P; Cieślik MP; Giordano TJ; Chinnaiyan AM; Dhanasekaran SM; Mehra R
    Eur Urol; 2020 Jul; 78(1):63-74. PubMed ID: 32299640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.